Clonucopya: An end-to-end workflow bridging tumor clonal architecture and drug prioritization
- 1Spanish National Cancer Research Center
Abstract
Motivation: Intra-tumor heterogeneity limits the effectiveness of anticancer treatments, as distinct clonal populations may respond differently to therapy. Although subclonal inference from sequencing data is well established, translating clonal architecture into actionable drug recommendations remains a major bottleneck. Results: We present Clonucopya, an end-to-end Snakemake workflow that integrates subclonal inference (PyClone-VI, PhyClone) with drug prioritization (PanDrugs2) to link tumor clonal architecture directly to candidate drugs. From genome sequencing data, Clonucopya reconstructs tumor phylogenies, quantifies clone-level prevalence across samples, and ranks FDA/EMA-approved and experimental therapeutic candidates against the somatic mutations detected in each clone. Outputs include clonality plots, per-clone variant and drug tables, and a summary ranking drugs by clonal coverage to highlight broadly active therapeutic candidates. We assess Clonucopya's utility through a real-world longitudinal, multi-region use case, revealing clinically actionable clonal dynamics across tumor progression.
Related
- An Integrated Miniaturized Metabologenomics Workflow for High-Throughput Actinomycetes Prioritization
- Spatiotemporal Clonal Architecture of the Newborn Mouse Forebrain
- Brain FACTs: A same-section workflow for Fiber Architecture, Cytoarchitecture and cell Types in large-scale brain sections
- In utero barcoding of mouse mesoderm reveals the clonal architecture of organ mesenchyme
- Clonal expansion of HTLV-1 infected cells depends on the CD4 versus CD8 phenotype
BibTeX
@misc{sanchezcid2026clonucopya,
title = {{Clonucopya: An end-to-end workflow bridging tumor clonal architecture and drug prioritization}},
author = {G. Sanchez-Cid and C. Leon-Ramos and E. Pineiro-Yanez and G. Gomez-Lopez and F. Al-Shahrour},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.08.757690},
url = {https://www.biorxiv.org/content/10.64898/2026.10.08.757690v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Clonucopya: An end-to-end workflow bridging tumor clonal architecture and drug prioritization
AU - G. Sanchez-Cid
AU - C. Leon-Ramos
AU - E. Pineiro-Yanez
AU - G. Gomez-Lopez
AU - F. Al-Shahrour
PY - 2026
DA - 2026/10/08
PB - bioRxiv
DO - 10.64898/2026.10.08.757690
UR - https://www.biorxiv.org/content/10.64898/2026.10.08.757690v1
AB - Motivation: Intra-tumor heterogeneity limits the effectiveness of anticancer treatments, as distinct clonal populations may respond differently to therapy. Although subclonal inference from sequencing data is well established, translating clonal architecture into actionable drug recommendations remains a major bottleneck. Results: We present Clonucopya, an end-to-end Snakemake workflow that integrates subclonal inference (PyClone-VI, PhyClone) with drug prioritization (PanDrugs2) to link tumor clonal architecture directly to candidate drugs. From genome sequencing data, Clonucopya reconstructs tumor phylogenies, quantifies clone-level prevalence across samples, and ranks FDA/EMA-approved and experimental therapeutic candidates against the somatic mutations detected in each clone. Outputs include clonality plots, per-clone variant and drug tables, and a summary ranking drugs by clonal coverage to highlight broadly active therapeutic candidates. We assess Clonucopya's utility through a real-world longitudinal, multi-region use case, revealing clinically actionable clonal dynamics across tumor progression.
ER -